The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.
Informed oral and written consent.
Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.
Currently seeking to cut down or stop cannabis use.
Positive urine test for cannabinoids.
Currently meeting non-cannabis/tobacco substance use disorder (ICD-10 or DSM-5).
Current or past diagnosis of severe psychiatric illness, defined as schizophrenia, bipolar disorder, or other psychoses, within the past five years.
Suicide attempt or suicidal behavior within the past five years.
Severe neurological disorders, including previous severe traumatic brain injury, stroke, or intracranial hemorrhage.
Anders Fink-Jensen, MD, DMSci
Lead sponsor
Psychiatric Centre Rigshospitalet
Sponsor institution